Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's
Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications spinal cord injury (SCI) and Alzheimer's disease (AD) that have bedeviled biotechs and big pharmas, alike.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST